Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
PR Newswire•05/10/2026•08:15 ET
0
Key Highlights
- ➤First stable disease response observed 90 days after ovarian cancer CAR-T treatment
- ➤Highest dose cohort patient received 1×10⁷ CAR-positive cells per kilogram
- ➤No dose-limiting toxicities observed across the Phase 1 trial to date
- ➤Multiple patients survived beyond one year, including one beyond two years
Expert Statements
Amit Kumar, Chairman and CEO of Anixa Biosciences
“While this Phase 1 study is primarily designed to evaluate safety, we are encouraged by our early anecdotal findings of overall survival (OS). In addition, an observation of stable disease for this duration, coupled with multiple patients having surpassed one year of survival following treatment, is very encouraging as we look forward to further evaluating lira-cel at current and future dose levels.”
Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt and principal investigator for the trial
“As we advance in this trial we hope to continue observing improved results in patients, from progressive disease to stable disease and eventually to radiological partial response (PR) and hopefully complete response (CR). This result, and the absence of dose-limiting toxicities observed thus far is encouraging as we continue to treat patients in the current and future dose cohorts.”
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial PR Newswire
First patient in current dose cohort exhibited no progression of her cancer three months after treatment
Get started
Create a free account to read the full story.